Zobrazeno 1 - 7
of 7
pro vyhledávání: '"G E, Konopleva"'
Autor:
M. A. Kolganova, N. S. Bagaeva, Yu. V. Medvedev, I. E. Shohin, A. V. Demchinskaya, T. N. Palkina, D. A. Salazanov, G. E. Konopleva, M. S. Sheremeteva, Sh. Z. Archuadze, Ya. V. Lavrovsky, A. Yu. Savchenko, M. Yu. Samsonov
Publikováno v:
Разработка и регистрация лекарственных средств, Vol 8, Iss 3, Pp 91-100 (2019)
Introduction. Bevacizumab is a monoclonal IgG1 antibody that binds to and inhibits the biologic activity of human vascular endothelial growth factor (VEGF). Bevacizumab is used as a targeted monoor combination therapy for different solid tumors. Phas
Externí odkaz:
https://doaj.org/article/6934a7f8205e43d19cd8c3495b30f189
Autor:
K. L. Kryshen, A. A. Muzhikyan, D. S. Gaidai, K. O. Zaikin, A. E. Katelnikova, M. Yu. Samsonov, E. I. Mukhametshina, G. E. Konopleva, E. V. Shipaeva, A. A. Dmitrieva, F. S. Shagiakhmetov, A. O. Popova, M. N. Makarova, V. G. Makarov
Publikováno v:
Issledovaniâ i Praktika v Medicine, Vol 6, Iss 2, Pp 58-68 (2019)
Opioid receptor antagonists are widely used for the treatment of alcohol dependence. Currently, original drug Odelepran (INN: ondelopran) with a unique binding profi le to all three types of human opioid receptors (μ, κ, δ) is being developed by
Externí odkaz:
https://doaj.org/article/cc97aa7303954c77ba50c93ca8d5605d
Autor:
Mikhail Yu. Samsonov, Sergei Barbashov, G. E Konopleva, A. A Dmitrieva, Ya. V Lavrovsky, E. Shipaeva
Publikováno v:
Medical Journal of the Russian Federation. 24:324-331
Nonclinical studies of biotechnology-derived medicinal products are discussed in the article in terms of new original fusion protein RPH-104 - high potency IL-1β signal pathway antagonist. Specificity of biotherapeutics is connected to complexity of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ee4463348d823c4406c8290e3fbd158b
https://doi.org/10.18821/0869-2106-2018-24-6-324-331
https://doi.org/10.18821/0869-2106-2018-24-6-324-331
Autor:
G. E. Konopleva, I. V. Skul'te, É. T. Oganesyan, A. V. Simonyan, Yu. K. Vasilenko, E. P. Parfent'eva
Publikováno v:
Pharmaceutical Chemistry Journal. 25:552-555
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::605175e01c3adde9af9935b76a6a86e6
https://doi.org/10.1007/bf00777423
https://doi.org/10.1007/bf00777423
Publikováno v:
Annals of Oncology. 26:ix111
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e28eb160960a054853d7c931d547d114
https://doi.org/10.1093/annonc/mdv531.04
https://doi.org/10.1093/annonc/mdv531.04
Publikováno v:
Pharmaceutical Chemistry Journal. 25:877-879
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::10110e9f077a52c4705706494d3d159b
https://doi.org/10.1007/bf00778977
https://doi.org/10.1007/bf00778977
Autor:
Iu K, Vasilenko, V F, Semenchenko, L M, Frolova, G E, Konopleva, E P, Parfent'eva, I V, Skul'te
Publikováno v:
Eksperimental'naia i klinicheskaia farmakologiia. 56(4)
The birch bark was used to prepare the summary triterpenic drug betulenol and its diacetate. Rat experiments with models of abnormalities revealed their hypolipidemic, cholagogic, antilithogenic and hepatoprotective activities which were higher than
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::ad5da21f9a61284870afffccdd54f3fc
https://pubmed.ncbi.nlm.nih.gov/8220020
https://pubmed.ncbi.nlm.nih.gov/8220020